Clinical Trials Browser

Phase 2 × Hematologic Diseases × lintuzumab × Clear all

NCT00528333 2015-01-07

A Study of Lintuzumab (SGN-33) in Combination With Low Dose Cytarabine in Patients 60+ Years With AML

Phase 2 Completed

Other hematologic neoplasm

Hematologic Diseases, Leukemia, Leukemia, Myeloid, Acute